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The shared genetic basis of attention deﬁcit/hyperactivity disorder (ADHD) and substance use
disorders (SUDs) was explored by investigating the association of candidate risk factors in
neurotransmitter genes with both disorders. One hundred seven methadone maintenance
treatment patients, 36 having an ADHD diagnosis, 176 adult patients with ADHD without SUDs,
and 500 healthy controls were genotyped for variants in the DRD4 (exon 3 VNTR), DRD5
(upstream VNTR), HTR1B (rs6296), DBH (rs2519152), COMT (rs4680; Val158Met), and OPRM1
(rs1799971; 118A4G) genes. Association with disease was tested using logistic regression
models. This pilot study was adequately powered to detect larger genetic effects (ORZ2) of
risk alleles with a low frequency. Compared to controls, ADHD patients (with and without SUDs)
showed signiﬁcantly increased frequency of the DBH (rs2519152: OR 1.73; CI 1.15–2.59;
P=0.008) and the OPRM1 risk genotypes (rs1799971: OR 1.71; CI 1.17–2.50; P=0.006).Elsevier B.V. and ECNP. All rights reserved.
o.2012.07.003
an Arkel group’s-Hertogenbosch, The Netherlands.
6706.
ail.com (P.J. Carpentier).
Genetic markers of ADHD and addiction 449The DBH risk genotype was associated with ADHD diagnosis, with the association strongest in
the pure ADHD group. The OPRM1 risk genotype increased the risk for the combined ADHD and
SUD phenotype. The present study strengthens the evidence for a shared genetic basis for ADHD
and addiction. The association of OPRM1 with the ADHD and SUD combination could help to
explain the contradictory results of previous studies. The power limitations of the study restrict
the signiﬁcance of these ﬁndings: replication in larger samples is warranted.
& 2012 Elsevier B.V. and ECNP. All rights reserved.1. Introduction
Both attention deﬁcit/hyperactivity disorder (ADHD) and
substance use disorders (SUDs) are quite prevalent, with
estimated prevalences in the adult population of 3.4% and
9.2% respectively (Fayyad et al., 2007; Substance Abuse and
Mental Health Services Administration, 2007). These dis-
orders are highly heritable and are accompanied by sub-
stantial rates of psychiatric comorbidity. Moreover, they
frequently coexist (Wilens, 2007). Although there are clear
indications that the psychiatric symptoms and conduct
disturbances associated with ADHD have a causative role
in the development of problematic drug use and addiction
(Elkins et al., 2007; Roy, 2008), there are also indications of
a genetic basis for the overlap (Groman et al., 2009; Wilens,
2004). ADHD is more prevalent in families of probands
with SUDs (Clark et al., 2004; Knopik et al., 2009;
Marmorstein et al., 2009; Wilens et al., 2005), and SUDs
are more frequent among family members of ADHD patients
(Biederman et al., 1992; Faraone et al., 2000; Milberger
et al., 1998). Indeed, a study assessing both ADHD and SUDs
in families of ADHD probands revealed evidence for a shared
familiality of ADHD and drug use disorders with variable
expression (Biederman et al., 2008).
The genetic risk factors common to ADHD and SUDs have
not yet been identiﬁed, mostly because the etiologies of the
two disorders are still largely unknown. The most attention
has been focused on neurotransmitter systems involved in
the pathophysiology of the two disorders, especially the
dopaminergic system; dopamine is the primary neurotrans-
mitter of the central motivation system, which plays a
crucial role in addiction (Koob and Volkow, 2010;
Volkow et al., 2009). Dopamine is also implicated in ADHD,
mainly due to the therapeutic effects of stimulant medica-
tion, which inhibits the reuptake of dopamine (Biederman
and Faraone, 2005; Tripp and Wickens, 2009). Serotonin
dysregulation is also hypothesised to play a causal role in
ADHD and addiction (Oades, 2008; Ribases et al., 2009;
Ross and Peselow, 2009). Genetic determinants of
variability in these neurotransmitter systems have been
studied in both disorders, with controversial results
(Faraone et al., 2005; Kreek et al., 2005; Yuferov et al.,
2010). In cases where particular variants conveying an
increased risk were described, the results have proven
difﬁcult to reproduce. This is because the impact of each
variant is quite small, attesting to the polygenic nature of
the two disorders (Faraone and Mick, 2010; Wong and
Schumann, 2008).
Direct comparison studies of risk genotypes in different
patient populations are rather scarce. A recent assembly of
both clinical and genetic data from different populationsallowed us to explore the role of a limited number of
genetic polymorphisms in the proposed shared predisposi-
tion to ADHD and SUDs. Due to the limited size of the
project, a pragmatic choice was made to study six well-
documented polymorphisms of the genes DRD4, DRD5,
HTR1B, DBH, COMT, and OPRM1, previously used in associa-
tion studies of ADHD and/or SUDs. It is important to point
out that most family studies on the genetics of ADHD
(indeed, most of the studies mentioned below) were carried
out in child and adolescent populations. However the
available scientiﬁc information indicates that the heritabil-
ity of clinically diagnosed childhood and adult ADHD is quite
similar. Moreover results of candidate gene as well as
genome-wide molecular genetic studies in adult ADHD
samples implicate some of the same genes involved in ADHD
in children, although in some cases different alleles and
different genes may be responsible for adult versus child-
hood ADHD (Franke et al., 2011).
The dopamine D4 and D5 receptors are well represented
in the frontal–subcortical networks implicated in the patho-
physiology of ADHD, as shown by neuroimaging and neurop-
sychological studies (Brennan and Arnsten, 2008; Curatolo
et al., 2009). Most molecular genetic studies of DRD4 in
ADHD have focused on a variable number of tandem repeat
polymorphisms (VNTRs), which consist of a 48 base-pair (bp)
repeat unit that codes an amino-acid sequence located in
the third cytoplasmic loop of the receptor. This sequence is
thought to be involved in G-protein coupling (DiMaio et al.,
2003). The association of the 7-repeat allele with ADHD has
been conﬁrmed in three meta-analyses (Faraone et al.,
2005; Gizer et al., 2009; Li et al., 2006), and was used as
the risk allele in this study. The DRD4 polymorphism has not
been studied extensively in substance use disorders, except
for a Hungarian study of addicted patients which failed to
reveal a signiﬁcant association with addiction (Szilagyi
et al., 2005). The most widely studied polymorphism, our
choice for this study, of the dopamine D5 receptor (DRD5) is
a dinucleotide repeat that maps approximately 18.5 kb
upstream of the transcription start site (Hawi et al.,
2003). The common 148-bp repeat allele is clearly asso-
ciated with ADHD (Gizer et al., 2009; Li et al., 2006; Lowe
et al., 2004; Maher et al., 2002). No signiﬁcant association
of this allele with SUDs has yet been identiﬁed (Le Foll
et al., 2009).
Serotonin dysregulation has been related to impulsive
behaviour (Dalley et al., 2008) and thus hypothesised to
play a causal role in ADHD. A modest but signiﬁcant
association between ADHD and a G4C transition at nucleo-
tide position 861 (861G4C; rs6296) of the serotonin 1b
receptor (HTR1B; 5-HT1B) gene has been conﬁrmed in a
recent meta-analysis (Gizer et al., 2009; Hawi et al., 2002)
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serotonin system is also involved in drug and alcohol
dependence, the role of this same single nucleotide poly-
morphism (SNP) has been studied in addiction, and its
association with a history of substance use disorder has
been reported in three studies (Yuferov et al., 2010).
However, no association with the rs6296 SNP was found in
a study of heroin addiction, although nominally signiﬁcant
associations of heroin dependence with other polymorph-
isms in the HTR1B genome were identiﬁed (Proudnikov
et al., 2006).
Dopamine beta-hydroxylase (DBH) is the primary enzyme
responsible for the conversion of dopamine to norepinephr-
ine. A signiﬁcant association of ADHD with a SNP in intron
5 of the DBH gene, which results in the creation of a TaqI
restriction enzyme site sequence (rs2519152), was ﬁrst
reported by Daly et al. (1999). A recent meta-analysis of
attempted replications of this ﬁnding failed to reach
statistical signiﬁcance, indicating a trend towards an asso-
ciation of rs2519152 with ADHD (Gizer et al., 2009); we took
this variant as our risk polymorphism. There have been few
studies of SUD associations and these have yielded incon-
sistent results (Kreek et al., 2005).
Catechol-O-methyl-transferase (COMT) is responsible for
the degradation of the catecholamines dopamine and
norepinephrine. This enzyme is very active in the frontal
lobe, where it plays an important role in regulating synaptic
dopamine levels. The most studied polymorphism of COMT is
a functional SNP that generates a valine to methionine
substitution (Val158Met), which results in decreased enzy-
matic activity and increased dopamine in the prefrontal
cortex (Chen et al., 2004). Studies of this variation in ADHD
have yielded equivocal results, and a recent meta-analysis
indicates no association of this polymorphism with the
disorder (Gizer et al., 2009). However, the Val allele of
the Val158Met polymorphism has been linked with aggres-
siveness and conduct disorder symptoms; this association
with conduct disorder has been replicated in ADHD patients
(Caspi et al., 2008; Deyoung et al., 2009; Langley et al.,
2010). Among all the childhood psychiatric disorders, con-
duct disorder carries the highest risk of later SUD develop-
ment (Roy, 2008). In the present study the Val allele was
considered the risk allele.
The OPRM1 gene codes for the m-opioid receptor, which is
the molecular target for endogenous opioid peptides as well
as for morphine and other opioids. Due to this receptor’s
crucial role in opioid tolerance and dependence, variations
in its genetic code receptor have been implicated not
only in opioid dependence but also in other SUDs. As our
risk variant we took one of the most studied variants of the
receptor genome is the 118A4G (rs1799971) SNP, which
alters the amino acid sequence of the receptor. Although
some studies have found a signiﬁcant association of this SNP
with opioid dependence (Bart et al., 2004; Drakenberg
et al., 2006; Kreek et al., 2005) and other SUDs (van der
Zwaluw et al., 2007), a recent meta-analysis found no
signiﬁcant evidence for either a dominant or additive
effect of this polymorphism on the risk of opioid dependence
(Glatt et al., 2007). Although there have been no investiga-
tions of this variant in ADHD, recent research suggests a
role for the opioid system in impulse control disorders
(Olmstead et al., 2009).Starting from the hypothesis of a shared genetic basis for
ADHD and SUDs, we proposed that some risk genotypes are
associated with one of them alone, whereas others are
associated with their combination. We tested this hypoth-
esis in an exploratory study using genetic material from
three previous studies. However, not enlarging our study
samples and using only available material restricted the
possibility to sufﬁciently power the study for optimal
signiﬁcance.2. Materials and methods
2.1. Study populations
In the present analysis genetic material from three different study
samples was used:1) Methadone maintenance patients (n=107, 81.3% men, mean age
41.2 years, age range 24–59). An extensive assessment was recently
performed of the psychiatric comorbidity (including ADHD) of 197
opioid-dependent patients in long-term methadone maintenance
treatment (Carpentier et al., 2012, 2009, 2011). ADHD diagnoses
were based on information obtained from semi-structured inter-
views. The interview protocol, which is based on the DSM-IV
deﬁnition of ADHD, assesses both the childhood and current
presence of three symptom classes (inattention, restlessness, and
impulsivity) and the resulting dysfunction (Kooij, 2002; Kooij et al.,
2008, 2004). If possible, partners or relatives were contacted to
conﬁrm the information. During this study a majority of participants
agreed to provide a blood or saliva sample for genetic analysis.
Patients of non-Caucasian origin were excluded from the analyses
reported here, as were patients with an insufﬁciently substantiated
ADHD diagnosis. This left us with a ﬁnal selection of 107 samples,
from 36 patients diagnosed as having ADHD and 71 patients
diagnosed as not having ADHD respectively.2) Adult ADHD patients (n=176, 47.7% men, mean age 37.1 years,
age range 18–65). Adult patients with persistent ADHD were
recruited as part of the International Multicentre Persistent
ADHD CollaboraTion (IMpACT) (Franke et al., 2010) from two
treatment centres in The Netherlands. All patients were eval-
uated by experienced psychiatrists; the diagnosis of persistent
ADHD was based on DSM-IV criteria (Franke et al., 2008). All the
patients were ethnic Caucasian. Screening for SUDs was part of
the clinical evaluation.3) Healthly control subjects (n=500, 49.4% men, mean age 59.4
years, age range 22–92). Controls of Caucasian origin were
recruited as part of the Nijmegen Biomedical Study
(Hoogendoorn et al., 2006), a population-based survey con-
ducted by the Department of Epidemiology and Biostatistics
and the Department of Clinical Chemistry of the Radboud
University Nijmegen Medical Centre. A random sample of
21,756 residents of the municipality of Nijmegen, stratiﬁed by
age and sex, received an invitation to ﬁll out a postal ques-
tionnaire on lifestyle and medical history. Forty-three per cent of
the sample (N=9350) returned valid questionnaires; 69% of
participants (N=6468) also donated a blood sample. The subjects
were asked to complete the adult ADHD DSM-IV-TR Rating Scale
for current symptoms (Kooij et al., 2005). All those reporting
four or more positive symptoms on this screening list were
excluded from the analyses. The control group was not speciﬁ-
cally screened for SUDs.
For all three samples, the approval of the study design and
proceduce by the appropriate ethics committee and the informed
consent procedure are documented in the original study reports
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2006). Groups and subgroups based on ADHD and SUD status were
formed from the two patient samples (Table 1). The ADHD_all group
included all patients with ADHD (both with and without SUDs). The
ADHD_pure subgroup was restricted to patients with ADHD only. The
ADHD&SUD_pure subgroup consisted of patients with both disor-
ders. Patients with SUDs only formed the SUD_pure subgroup.
Finally, the SUD_all group included all patients with SUDs.2.2. Laboratory methods
Genotyping was performed on DNA isolated from blood or saliva
using standard protocols. Generally, 5% blanks as well as duplicates
in and between plates were included as quality controls during
genotyping. All genetic analyses were performed at a CCKL-
certiﬁed laboratory at the Department of Human Genetics in
Nijmegen.
Genotyping of DRD4 (exon 3 VNTR) and DRD5 (upstream VNTR)
was performed using Fragment Length Analysis. The PCR reaction of
the DRD4 was assessed using 50 ng of genomic DNA, 1.25 mM of the
ﬂuorescent-labelled forward primer 50-Vic-GCGACTACGTGGTC-
TACTCG-30, 1.25 mM of the reverse primer with PIG tail
(50-AGGACCCTCATGGCCTTG-30), 0.4 mM dNTPs, TaKaRa 1 GCI
Buffer TaKaRa (2 ), 0.5 U TaKaRa LA TaqTM polymerase (Lucron
Bioproducts B.V, Gennep, the Netherlands), and 1 M Betaine.
Ampliﬁcation was initiated by a denaturation step at 94 1C for
1 min, followed by 35 cycles of 30 s at 94 1C, 30 s at 58 1C, 1 min at
72 1C, and a ﬁnal step of 5 min at 72 1C. The DRD5 upstream VNTR
was ampliﬁed using 50 ng of genomic DNA, 1 mM of the ﬂuorescent-
labelled forward primer (50-FAM-GCTCATGAGAAGAATGGAGTG-30),
1 mM of the reverse primer with PIG tail (50-CGTGTATGATCCCTG-
CAG-30), 0.25 mM of dNTPs, 2.5 mM of MgCl2, 1 PCR buffer II
(10 ; Applied Biosystems, Nieuwerkerk aan de Ijssel, The Nether-
lands), and 0.4 U of AmpliTaq Gold Polymerase (Applied Biosys-
tems). The PCR reaction was obtained through an initial
denaturation step of 12 min at 92 1C, followed by 35 cycles of
30 s at 92 1C, 30 s at 55 1C, 1 min at 72 1C, and ﬁnally 10 min at
72 1C. The PCR-products of DRD4 and DRD5 were combined by
diluting the DRD4 product 100 times and the DRD5 product 10 times.
One microliter of the result, combined with 9.7 ml of formamide and
0.3 ml of Genescan-600 LIZ Size Standard (Applied Biosystems), was
analysed using a 3730 Genetic Analyzer (Applied Biosystems)
according to the protocol of the manufacturer.
The HTR1B polymorphism rs6296 was genotyped using a Taqman
analysis (assay ID: Taqman assay: C___2523534_20 Applied Biosys-
tems). Genotyping was performed in a 10 ml solution containing
10 ng of genomic DNA, 5 ml of Taqman Mastermix (2 ; Applied
Biosytems), 0.125 ml of the Taqman assay, and 3.875 ml of water,
using a 7500 Fast Real-Time PCR System. The genotypes were
scored using the algorithm and software supplied by the manufac-
turer (Applied Biosystems).Table 1 Gender distribution in the study populations, and for
and SUD status from two patient samples (MMT patients: N=107
N N Male (%) n ADHD_all n
N 212 1
N Male (%) 52.4 4
N MMT patients with ADHD 36 27 (75.0) 36
N MMT patients without ADHD 71 60 (84.5)
N ADHD patients 176 84 (47.7) 176 1
Controls 500 247 (49.4)
MMT: methadone maintenance treatment.The DBH polymorphism rs2519152 was genotyped using a restric-
tion-fragment length polymorphism (RFLP) analysis. PCR was per-
formed on 50 ng of genomic DNA using 0.4 mM of the forward primer
50-AGGCATTTTACTACCCAGAGG-30, 0.4 mM of the reverse primer 50-
CTGTATTTGGAACTTGGCATC-30, 0.25 mM of dNTPs, and 0.5 U of Taq
DNA polymerase (Invitrogen, Breda, The Netherlands) in a PCR
buffer containing 10 mM of Tris-HCl pH 8.0, 50 mM of KCl, 0.1%
Triton X-100 (v/v), 0.015% gelatin (w/v), 5% DMSO (v/v), and
1.5 mM of MgCl2. The cycling conditions were 5 min at 92 1C,
followed by 35 cycles of 1 min at 92 1C, 1 min at 61 1C, 1 min at
72 1C, and lastly 10 min at 72 1C. To purify the PCR-product,
NucleoFast96 plates (Macherey-Nagel, Du¨ren, Germany) were used.
An enzyme restriction reaction was subsequently produced in a
15 ml solution consisting of 10 ml of puriﬁed PCR-product, 5 U of TaqI
restriction enzyme, 1 NEBuffer 3, and 1 bovine serum albumin.
Digestion was produced at 65 1C for 4 h, which resulted in two
fragments of 297 bp and 167 bp for the homozygous T genotype; the
homozygous C variant remained uncut (464 bp).
The COMT polymorphism (rs4680) was genotyped using Taqman
analysis (assay ID: Taqman assay: C__25746809_50; reporter 1: VIC-
A-allele, reverse assay; Applied Biosystems), in a 10 ml solution
consisting of 10 ng of genomic DNA, 5 ml of Taqman Mastermix (2 ;
Applied Biosytems), 0.125 ml of the Taqman assay, and 3.875 ml of
water, on a 7500 Fast Real-Time PCR System. The genotypes were
scored using the algorithm and software supplied by the manufac-
turer (Applied Biosystems).
The OPRM1 polymorphism (rs1799971) was genotyped again using
Taqman analysis (assay ID: Taqman assay: C___8950074_1_; repor-
ter 1: VIC-A-allele, forward assay; Applied Biosystems), in a 10 ml
solution consisting of 10 ng of genomic DNA, 5 ml of Taqman
Mastermix (2 ; Applied Biosytems), 0.25 ml of the Taqman assay,
and 3.75 ml of water, and performed on a 7500 Fast Real-Time PCR
System. The genotypes were scored using the algorithm and soft-
ware supplied by the manufacturer (Applied Biosystems).2.3. Statistical analysis
We determined allelic frequencies in all three samples. Starting
from a dominant model of inheritance for each risk allele, we
calculated the frequency of the risk allele carriers (both homo-
zygous and heterozygous) in the different groups and subgroups. For
each risk polymorphism we deﬁned the risk group/genotype as
comprising both the homozygous and heterozygous carriers of the
minor allele (in case of HTR1B and OPRM1), the major allele for
DBH, the Val-allele for COMT, the 7-repeat allele for DRD4 and the
148-bp repeat allele for DRD5.
Hardy–Weinberg equilibrium (HWE) was assessed for each genetic
variant tested using standard methods and using a p-value cut-off of
0.05. To analyse the association between the selected genetic
variants and the risk of ADHD, a logistic regression was performed
comparing the ADHD_all group and the control group with gender as
the covariate. To account for multiple analyses, the signiﬁcancemation of comparison groups and subgroups based on ADHD
; ADHD patients: N=176).
ADHD_pure n ADHD&SUD _pure n SUD_pure n SUD_all
76 36 71 107
7.7 75.0 84.5 81.3
36 36
71 71
76
P.J. Carpentier et al.452level was adjusted using a Bonferroni correction (P/n: signiﬁcance
level divided by number of tests). If a risk genotype showed a
signiﬁcant increase in the odds ratio (OR), a post-hoc logistic
regression was carried out for this genotype in each patient group
and subgroup compared to the control group, again with gender as a
covariate. As the subgroup analysis explored the basis of the
associations found in the entire group, an additional Bonferroni
adjustment was deemed to be an overcorrection, and the same
corrected signiﬁcance level was used. All statistical analyses were
performed using Statistical Package for the Social Sciences 15.0.1,
2006 (SPSS Inc., Chicago, Ill., USA).
Performing a power analysis using the ‘Genetic Power Calculator’
(http://pngu.mgh.harvard.edu/~purcell/gpc/) we found that at a
power level of 0.80, assuming a dominant model of inheritance and
perfect linkage desequilibrium between the causal variant and the
markers used, the study is adequately powered to detect in the
total group (ADHD patients: N=283) larger genetic effects (ORZ2)
of risk alleles with a moderate (=0.25) to low (r0.10) frequency.
3. Results
The prevalence of the six risk allele carriers in the different
groups and subgroups is listed in Table 2. Table 3 shows the
ORs for the risk allele carriers in the ADHD_all group
compared to the control group. After the Bonferroni
correction, a signiﬁcant association with disease was foundTable 2 Frequency of six risk allele carriers (both homozygo
patients with ADHD and/or SUD.
N % Male ADHD_all A
212 1
52.4 4
DRD4 VNTR-48bpVNTR risk group (7R-carriers) 30.4 2
DRD5 VNTR-2 bpVNTR risk group (148-bp carriers) 66.5 6
HTR1B 861G4C (rs6296) risk group (C-carriers) 44.8 4
DBH-intron5-C4T (rs2519152) risk group
(C-carriers)
78.8 8
COMT-VALMET-G4A (rs4680) risk group (G-4 Val-
carriers)
69.3 7
OPRM1 118A4G (rs1799971) risk group (G-carriers) 27.0 2
Table 3 Odds ratios of six risk allele carriers (homozygous an
without SUD: ADHD_all) compared to the control group (=ADHD
%
ADHD_all
DRD4 VNTR-48bpVNTR risk group (7R-carriers) 30.4
DRD5 VNTR-2bpVNTR risk group (148-bp carriers) 66.5
HTR1B 861G4C (rs6296) risk group (C-carriers) 44.8
DBH-intron5-C4T (rs2519152) risk group (C-carriers) 78.8
COMT-VALMET-G4A (rs4680) risk group (G-4Val-
carriers)
69.3
OPRM1 118A4G (rs1799971) risk group (G-carriers) 27.0
nSigniﬁcant after Bonferroni correction (signiﬁcance criterion: P=for the DBH (OR 1.73; CI 1.15–2.59; P=0.008) and the OPRM1
(OR 1.71; CI 1.17–2.50; P=0.006) risk genotypes. The
covariate Gender had no signiﬁcant effect.
A more detailed analysis of these two risk allele carriers
in the different patient groups revealed clearly divergent
patterns (Table 4). The DBH risk genotype (comprising
homozygous and heterozygous expressions of the DBH-
intron5-C4T allele) was speciﬁcally associated with ADHD
diagnosis, with the highest OR in the ADHD_pure subgroup
(ADHD but not SUD: OR 1.97; CI 1.25–3.10; P=0.003). For
the OPRM1 risk genotype (the homozygous and heterozygous
OPRM1 118A4G genotypes), the largest OR was found in the
ADHD&SUD_pure subgroup (combined ADHD and SUDs: OR
2.75; CI 1.35–5.72; P=0.007). The covariate Gender
appeared to have an important effect in the SUD subgroups
(Table 4); this was due to the important gender disparity in
the SUD patient group.4. Discussion
The results of this exploratory investigation conﬁrm our
hypothesis that speciﬁc genotypes increase the risk for
ADHD only, whereas others convey an increased risk for
the combination of ADHD and SUD. The ﬁndings for the DBHus and heterozygous individuals) in different subgroups of
DHD_pure ADHD&SUD_pure SUD_pure SUD_all Controls
76 36 71 107 500
7.7 75.0 84.5 81.3 49.4
9.9 33.3 32.9 33.0 36.0
6.9 64.7 79.7 74.8 73.7
7.2 32.4 45.1 41.0 46.4
0.8 69.7 72.9 71.8 68.2
0.8 62.9 66.2 65.1 69.1
5.0 37.1 14.3 21.9 17.8
d heterozygous individuals) in patients with ADHD (with and
-/SUD-).
%
Controls
Genotype Sex
Adj
OR
95% CI P Adj
OR
95% CI P
36.0 0.78 0.55–1.10 0.16 1.10 0.79–1.52 0.58
73.7 0.70 0.18–1.02 0.066 1.17 0.82–1.66 0.38
46.4 0.94 0.68–1.29 0.69 1.10 0.80–1.53 0.54
68.2 1.73 1.15–2.59 0.008n 1.13 0.80–1.60 0.48
69.1 1.02 0.70–1.48 0.93 1.15 0.82–1.62 0.42
17.8 1.71 1.17–2.50 0.006n 1.12 0.81–1.54 0.50
0.05/6=0.00833).
Table 4 Odds ratios of DBH and OPRM1 risk allele carriers (homozygous and heterozygous individuals) in different subgroups
of patients with ADHD and SUD compared to the control group.
Genotype Sex
Adj OR 95% CI p Adj OR 95% CI p
DBH-intron5-C4T (rs2519152) risk group (C-carriers)
ADHD_all 1.73 1.15–2.59 0.008 1.13 0.80–1.60 0.48
ADHD-pure 1.97 1.25–3.10 0.003 0.94 0.65–1.37 0.75
ADHD&SUD_pure 1.05 0.49–2.28 0.89 2.76 1.26–6.07 0.011
SUD_pure 1.22 0.69–2.17 0.49 5.55 2.84–10.81 o0.001
SUD_all 1.15 0.71–1.86 0.57 4.29 2.55–7.21 o0.001
OPRM1 118A4G (rs1799971) risk group (G-carriers)
ADHD_all 1.71 1.17–2.50 0.006 1.12 0.81–1.54 0.50
ADHD-pure 1.54 1.02–2.32 0.040 0.94 0.67–1.33 0.73
ADHD&SUD_pure 2.75 1.32–5.72 0.007 2.98 1.36–6.51 0.006
SUD_pure 0.80 0.39–1.66 0.56 5.47 2.81–10.67 o0.001
SUD_all 1.35 0.79–2.30 0.28 4.38 2.61–7.35 o0.001
Genetic markers of ADHD and addiction 453risk genotype are in accordance with the literature: up to
now, only the association of this genotype with ADHD, but
not with SUD, has been replicated (Gizer et al., 2009; Kreek
et al., 2005). The present ﬁndings suggest that the incon-
sistent results in SUD patients could result from the
signiﬁcant prevalence of (undiagnosed) ADHD in these
patient populations (Levin et al., 1998; Schubiner et al.,
2000; Wilens, 2004).
The OPRM1 ﬁndings are interesting, as the association of
OPRM1 118A4G with the ADHD and SUD combination has not
been previously documented. In this study the increased
prevalence of the risk genotype in SUD groups was primarily
due to a concentration of the risk genotype in patients with
both SUD and ADHD, while the prevalence in patients with only
SUD was strikingly low (Table 2). Interestingly, this speciﬁc
association can help explain the contradictory ﬁndings for this
gene in previous studies of patients with SUD (Glatt et al.,
2007; van der Zwaluw et al., 2007); in these studies, the
inﬂuence of comorbid ADHD was not taken into account. As the
endogenous opioid system has not yet been implicated in
the neurobiology of ADHD, the connection between ADHD and
the risk genotype addressed in the present study remains
unclear, as it has not been examined in previous studies.
However, it is relevant to note that the opioid system could
be involved in the disturbances of reward and reinforcement
regulation, observed in ADHD, particularly the impaired signal-
ling of delayed rewards arising from disturbances in motiva-
tional processes (Sonuga-Barke, 2003). The same polymorphism
of the m-opioid receptor gene (OPRM1) has been associated
with dispositional and neural sensitivity to social rejection (Way
et al., 2009) and parent–child relations (Copeland et al., 2011),
implicating the opioid (reward) system in the regulation of
social relations and behaviour. The present ﬁndings suggest a
speciﬁc pathophysiological role for the opioid system in the
increased vulnerability to both behaviour disturbance (ADHD)
and problematic substance use.
Despite its small size, the present study conﬁrms the value of
recognising the shared heritability of ADHD and addiction, and
it demonstrates that taking comorbidity into account can help
us understand the association of psychiatric disorders withspeciﬁc genes. Further study of the genetic basis of addiction
in ADHD patients could allow us to determine whether these
genes exert their inﬂuence primarily at the neurobiological,
behavioural, or social/emotional level, thereby helping us
elucidate the pathophysiology and the link between the two
disorders.
As the genetics of ADHD remain largely undetermined,
assessing comorbidity in ADHD patients could be a productive
way to identify reliable subtypes of ADHD and create more
homogeneous study samples, thereby enabling a more speciﬁc
association of ADHD with genetic risk factors (Buitelaar, 2005;
Levy and Ebstein, 2009). The present ﬁndings also have
implications for patient care. Their replication could lead to
the identiﬁcation of the ADHD and SUD combination as a
speciﬁc genetic subtype of ADHD. Such identiﬁcation would
be in accordance with the observation that the risk for
problematic substance use is not evenly distributed among
ADHD patients. Indeed, the majority of ADHD patients do not
show problematic substance use. From both the therapeutic
and preventive perspectives, it is important to know in what
respects ADHD patients with increased SUD risk differ from
ADHD patients with no addiction and how much of this
increased risk is determined by genetic factors.
Conﬁrmation of the genetic vulnerability to SUD offers
the possibility of early identiﬁcation and targeted preven-
tive interventions for ADHD patients at genetically
increased risk for addiction. Treatment of children with
ADHD with stimulant medication has shown some promise in
diminishing but not eliminating the risk for later addiction
(Biederman et al., 2008; Wilens et al., 2003). A better
understanding of the genetic underpinnings of addiction
could help us identify which patients would beneﬁt most
from ADHD medication and which patients would be better
served by other interventions.
We are very fortunate that this pilot study, using material
from previous studies, yielded interesting results, meriting
further investigation. However, in view of its limitations a
cautious interpretation of the relevance of its results is
warranted. The present study was executed with small study
samples, leading to even smaller subgroups, restricting both
P.J. Carpentier et al.454the power to detect gene variants of lesser effect and the
statistical signiﬁcance of the present ﬁndings. This is particu-
larly true for risk alleles with higher frequency, such as the
DBH risk genotype used. The ORs we have found are most
likely inﬂated and suffering from the winner’s curse. The fact
that the surprisingly large OR of 2.75 for the OPRM1 risk
genotype was found in the smallest subgroup of the study
(N=36) raises even the possibility a false positive result due to
the small sample size. Moreover the study was performed
without the availability of a replication sample, and compar-
able studies are lacking in the present literature. This means
that the present ﬁndings should be regarded as assumptions,
needing replication in independent samples. Future compar-
able studies should optimally include at least 500 cases per
group. The intriguing results of this study indicate that further
genetic research on the intersection of ADHD and addiction
could well prove to be fruitful by elucidating the genetic basis
and pathophysiology of both disorders.
Role of funding source
The genetic data compared and discussed in the present study were
gathered during the course of three previous research projects:1) Methadone maintenance patients (n=107): This study was
entirely funded by Novadic-Kentron, the addiction treatment
service were these patients were in treatment. The funding
organisation had no further role in study design; in the collec-
tion, analysis and interpretation of data; in the writing of
the report; and in the decision to submit the paper for
publication.2) Adult ADHD patients (n=176): Dutch adult patients with persis-
tent ADHD were recruited as part of the International Multi-
centre Persistent ADHD CollaboraTion (IMpACT) from two
treatment centres in The Netherlands. The Dutch part of the
project was supported by the Hersenstichting Nederland (Fonds
Psychische Gezondheid). The funding organisation had no
further role in study design; in the collection, analysis and
interpretation of data; in the writing of the report; and in the
decision to submit the paper for publication.3) Healthly control subjects (n=500): Controls of Caucasian origin
were recruited as part of the Nijmegen Biomedical Study
(Hoogendoorn et al., 2006), a population-based survey con-
ducted by the Department of Epidemiology and Biostatistics and
the Department of Clinical Chemistry of the Radboud University
Nijmegen Medical Centre, in collaboration with the municipality
of Nijmegen and the GGD Regio Nijmegen. This research
project is jointly ﬁnanced by the above institutions, who had
no further role in study design; in the collection, analysis and
interpretation of data; in the writing of the report; and in the
decision to submit the paper for publication.
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